HK1180720A1 - 穩定的α-半乳糖苷酶及其用途 - Google Patents

穩定的α-半乳糖苷酶及其用途

Info

Publication number
HK1180720A1
HK1180720A1 HK13107909.0A HK13107909A HK1180720A1 HK 1180720 A1 HK1180720 A1 HK 1180720A1 HK 13107909 A HK13107909 A HK 13107909A HK 1180720 A1 HK1180720 A1 HK 1180720A1
Authority
HK
Hong Kong
Prior art keywords
alpha galactosidase
stabilized alpha
stabilized
galactosidase
alpha
Prior art date
Application number
HK13107909.0A
Other languages
English (en)
Inventor
Avidor Shulman
Ilya Ruderfer
Tehila Ben-Moshe
Talia Shekhter
Yaniv Azulay
Yoseph Shaaltiel
Tali Kizhner
Original Assignee
Protalix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2010/000956 external-priority patent/WO2011061736A1/en
Application filed by Protalix Ltd filed Critical Protalix Ltd
Publication of HK1180720A1 publication Critical patent/HK1180720A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
HK13107909.0A 2010-03-02 2013-07-05 穩定的α-半乳糖苷酶及其用途 HK1180720A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30948710P 2010-03-02 2010-03-02
PCT/IL2010/000956 WO2011061736A1 (en) 2009-11-17 2010-11-17 Alkaline alpha galactosidase for the treatment of fabry disease
US201161434503P 2011-01-20 2011-01-20
US201161434499P 2011-01-20 2011-01-20
PCT/IL2011/000209 WO2011107990A1 (en) 2010-03-02 2011-03-02 Stabilized alpha-galactosidase and uses thereof

Publications (1)

Publication Number Publication Date
HK1180720A1 true HK1180720A1 (zh) 2013-10-25

Family

ID=44121635

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13107909.0A HK1180720A1 (zh) 2010-03-02 2013-07-05 穩定的α-半乳糖苷酶及其用途

Country Status (24)

Country Link
EP (3) EP2542675B1 (zh)
JP (2) JP5758920B2 (zh)
KR (1) KR101928403B1 (zh)
CN (1) CN102933707B (zh)
AU (1) AU2011222452B2 (zh)
BR (2) BR122014021216A2 (zh)
CA (1) CA2791461C (zh)
DK (1) DK2865751T3 (zh)
ES (2) ES2606532T3 (zh)
FI (1) FIC20230032I1 (zh)
HK (1) HK1180720A1 (zh)
HR (1) HRP20200428T1 (zh)
HU (2) HUE030959T2 (zh)
IL (2) IL221741A (zh)
IN (1) IN2012MN02262A (zh)
NL (1) NL301249I2 (zh)
NO (1) NO2023041I1 (zh)
NZ (2) NZ623294A (zh)
PL (1) PL2865751T3 (zh)
RU (1) RU2604795C2 (zh)
SG (2) SG183558A1 (zh)
SI (1) SI2865751T1 (zh)
WO (1) WO2011107990A1 (zh)
ZA (1) ZA201206725B (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107990A1 (en) * 2010-03-02 2011-09-09 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
LT3272861T (lt) * 2011-01-20 2020-03-25 Protalix Ltd. Alfa-galaktozidazės kompozicijos
TWI642782B (zh) * 2013-10-23 2018-12-01 健臻公司 重組醣蛋白及其用途
HRP20230468T1 (hr) * 2014-12-22 2023-11-10 Codexis, Inc. Varijante ljudske alfa galaktozidaze
WO2016116966A1 (en) * 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
CN107429257B (zh) 2015-03-17 2022-02-15 艾丽法有限责任公司 糖基化溶酶体蛋白、生产方法和用途
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
AU2018205891A1 (en) * 2017-01-05 2019-08-15 Protalix Ltd. Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase
DK3636751T3 (da) * 2017-06-07 2024-01-29 Amano Enzyme Inc Lactase-bulkpulver og lactasepræparat
KR20210106537A (ko) 2018-12-20 2021-08-30 코덱시스, 인코포레이티드 인간 알파 갈락토시다제 변이체
IL302628A (en) 2020-11-03 2023-07-01 Protalix Ltd Modified orikaze and its uses
CN112176026A (zh) * 2020-11-06 2021-01-05 诺道中科(北京)生物科技有限公司 一种α-半乳糖苷酶活性的检测试剂盒
CN116254287A (zh) * 2022-11-24 2023-06-13 西北农林科技大学 玉米ZmAGA3基因用于提高植物耐旱性的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
CA2052728A1 (en) 1991-10-03 1993-04-04 Guy Ampleman Glycidyl azide polymer
US6329191B1 (en) * 1993-08-30 2001-12-11 Hawaii Biotechnology Group, Inc. DNA encoding recombinant coffee bean alpha-galactosidase
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US20050032211A1 (en) * 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
DE69839563D1 (de) * 1997-09-05 2008-07-10 Altus Pharmaceuticals Inc Kohlenhydrat-vernetzte glykoproteinkristalle
IL125423A (en) 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
RU2246318C2 (ru) * 1998-08-06 2005-02-20 Маунтэн Вью Фармасьютикэлз, Инк. Конъюгаты peg-уриказы и их использование
US7270972B1 (en) * 1999-04-02 2007-09-18 Ajinomoto Co., Inc. Process for producing subunit peptide originating in polymer protein
ATE453705T1 (de) 2002-05-15 2010-01-15 Agricultural Res Org Für alkalische a-galactosidasen codierende polynukleotidsequenzen und verfahren zur verwendung davon
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
EP1877099B1 (en) * 2005-04-06 2012-09-19 Genzyme Corporation Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety
EP1961816B1 (en) * 2005-11-18 2015-09-02 Tokyo Metropolitan Institute of Medical Science Novel highly functional enzyme having modified substrate-specificity
WO2008075957A1 (en) 2006-12-21 2008-06-26 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of fabry disease
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
EP1955712A1 (en) 2007-02-09 2008-08-13 Scil proteins GmbH Multimeric conjugate
BRPI0815324A2 (pt) 2007-08-20 2015-07-14 Protalix Ltd "conjugado protêico que contém sacarídeos, processo de separação do conjugado protêico que contém sacarídeos, composição farmacêutica do conjugado protêico que contém sacarídeos, uso do conjugado protêico que contém sacarídeos e composto do conjugado protêico que contém sacarídeos"
WO2011107990A1 (en) * 2010-03-02 2011-09-09 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof

Also Published As

Publication number Publication date
PL2865751T3 (pl) 2017-03-31
EP3088514B1 (en) 2018-11-28
BR112012022029A2 (pt) 2021-05-18
NZ602317A (en) 2014-04-30
HUS2300038I1 (hu) 2023-11-28
HRP20200428T1 (hr) 2020-06-12
IL253249B (en) 2020-08-31
CA2791461C (en) 2019-10-22
IL253249A (en) 2019-08-29
SG10201502609QA (en) 2015-05-28
IN2012MN02262A (zh) 2015-06-12
RU2604795C2 (ru) 2016-12-10
JP5871999B2 (ja) 2016-03-01
CA2791461A1 (en) 2011-09-09
JP2014237694A (ja) 2014-12-18
WO2011107990A1 (en) 2011-09-09
ES2708843T3 (es) 2019-04-11
KR20130056216A (ko) 2013-05-29
NL301249I2 (nl) 2023-12-14
ES2606532T3 (es) 2017-03-24
BR122014021216A2 (pt) 2021-06-01
CN102933707B (zh) 2015-09-30
EP3088514A1 (en) 2016-11-02
EP2865751A1 (en) 2015-04-29
HUE030959T2 (en) 2017-06-28
JP5758920B2 (ja) 2015-08-05
NO2023041I1 (no) 2023-11-01
EP2542675A1 (en) 2013-01-09
IL221741A (en) 2017-07-31
AU2011222452A1 (en) 2012-09-27
NL301249I1 (zh) 2023-11-08
SG183558A1 (en) 2012-10-30
FIC20230032I1 (fi) 2023-11-02
JP2013520986A (ja) 2013-06-10
AU2011222452B2 (en) 2015-09-03
KR101928403B1 (ko) 2018-12-14
EP2542675B1 (en) 2014-12-17
NZ623294A (en) 2015-10-30
CN102933707A (zh) 2013-02-13
RU2012141651A (ru) 2014-04-10
EP2865751B1 (en) 2016-09-14
BR112012022029B1 (pt) 2022-10-11
ZA201206725B (en) 2013-06-26
DK2865751T3 (en) 2017-01-09
SI2865751T1 (sl) 2017-01-31

Similar Documents

Publication Publication Date Title
HUS2100032I1 (hu) Helyettesített 5-fluor-1H-pirazolopiridin-származékok és alkalmazásuk
HUS2300038I1 (hu) Stabilizált alfa-galaktozidáz és ennek alkalmazásai
HK1206004A1 (zh) 巨大戟二萜醇- -酰化物 和巨大戟二萜醇- -氨基甲酸酯
HK1187049A1 (zh) 雙芳基連接的芳基三唑酮及其用途
EP2552953A4 (en) FRIZZLED-BINDING SUBSTANCES AND ITS USES
SG10201505475XA (en) Romidepsin solid forms and uses thereof
HRP20160922T1 (hr) Oligopeptidni spojevi i njihove uporabe
PL2605757T3 (pl) Preparaty oparte na nalbufinie i ich zastosowania
EP2582836A4 (en) PRPK-TPRKB MODULATORS AND ITS APPLICATIONS
EP2608785A4 (en) LIPOMA CYCLES AND ITS USES
PL2627668T3 (pl) Peptydy i ich zastosowanie
EP2529013A4 (en) NOVEL BETA GLUCOSIDASE AND USES THEREOF
EP2598631A4 (en) RECOMBINANT BACTERIUM AND ITS USE
EP2619580A4 (en) SOLUTION MICROARRAYS AND USES THEREOF
GB201017093D0 (en) Biomarkers and uses thereof
EP2638160A4 (en) NUCLIONS AND RIBOCAPSIDES
GB201020268D0 (en) Composition and uses
GB201019361D0 (en) Biosensor and uses thereof
GB201014319D0 (en) Compounds and uses thereof